 BASKING RIDGE, N.J., May 14, 2020 GLOBE NEWSWIRE -- electroCore, Inc. ECOR, a commercial-stage bioelectronic medicine company, today announced first quarter 2020 financial results and provided an operational update. Received 510k clearance from FDA to expand the gammaCore label into migraine prevention. Announced that Englands National Health Service NHS has exercised its option to extend the Innovation and Technology Payment ITP Program for the use of gammaCore nVNS in the treatment of cluster headache in adults, through September 2020. 